References
- Blode H, Schurmann R, Benda N. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone. Contraception 2008;77:171–6.
- Fotherby K, Akpoviroro J, Abdel-Rahman HA, . Pharmacokinetics of ethynyloestradiol in women for different populations. Contraception 1981;23:487–96.
- Fotherby K, Shrimanker K, Abdel-Rahman HA, . Rate of metabolism of norethisterone in women from different populations. Contraception 1979;19: 39–45.
- Goldzieher JW, Dozier TS, de la Pena A. Plasma levels and pharmacokinetics of ethynyl estrogens in various populations. I. Ethynylestradiol. Contraception 1980;21: 1–16.
- el-Raghy I, Back DJ, Makeram M, . Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. Contraception 1986;33:379–84.
- Mizuno M, Kuwabara Y, Taketani Y, . [Clinical pharmacokinetic study of Org5187 as a low-dose oral contraceptive]. Nippon Funin Gakkai Zasshi 1991;36:35–48.
- de Visser SJ, Uchida N, van Vliet-Daskalopoulou E, . Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE). Contraception 2003;68:195–202.
- Blode H, Wuttke W, Loock W, . A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 2000;5:256–64.
- Kuhnz W, Blode H, Zimmermann H. Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens. In: Oettel M and Schillinger E, eds. Handbook of experimental pharmacology, estrogens and antiestrogens II. Berlin: Springer-Verlag 1999:261–322.
- Blode H. Pharmacokinetics of drospirenone. Gynaecol Forum 2002;7:18–22.
- Blode H, Foidart JM, Heithecker R. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. Eur J Contracept Reprod Health Care 2001;6:167–71.
- Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat Endocrinol 2003;2:49–70.
- Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38.
- European Medicines Agency (EMEA). ICH Topic E 5 (R1) Ethnic factors in the acceptability of foreign clinical data. Accessed 22 August 2011 from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002842.pdf.
- Bayer HealthCare Pharmaceuticals Inc. YAZ® Label, Section 7.1 Effects of other drugs on combined hormonal contraceptives. Accessed 22 August 2011 from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021676s008lbl.pdf.